Chronic rejection and cell growth factors.
Vuillemin
T
T
Service de Néphrologie-Urologie, CHU de Bicêtre, Kremlin Bicêtre, France.
Legendre
C
C
Meduri
G
G
Larue
J R
JR
Goupy
C
C
Kriaa
F
F
Hiesse
C
C
Benoit
G
G
Senik
A
A
Kreis
H
H
Charpentier
B
B
D001706:Biopsy; D001794:Blood Pressure; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D004815:Epidermal Growth Factor / Q000096:biosynthesis; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis; D006084:Graft Rejection / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D006133:Growth Substances / Q000032:analysis / Q000096:biosynthesis*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007375:Interleukin-1 / Q000096:biosynthesis; D016030:Kidney Transplantation / Q000276:immunology / Q000473:pathology* / Q000502:physiology; D010982:Platelet-Derived Growth Factor / Q000096:biosynthesis; D016133:Polymerase Chain Reaction; D011507:Proteinuria; D012333:RNA, Messenger / Q000096:biosynthesis; D014158:Transcription, Genetic; D016212:Transforming Growth Factor beta / Q000096:biosynthesis; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D006133:Growth Substances; D007166:Immunosuppressive Agents; D007375:Interleukin-1; D010982:Platelet-Derived Growth Factor; D012333:RNA, Messenger; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D016222:Fibroblast Growth Factor 2; D004815:Epidermal Growth Factor